Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060996 · ClinicalTrials.gov registry record · Phase 3
Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures
A Phase 3 study, sponsored by United Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT00060996 is a Phase 3 study that was terminated before completion, run by United Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT00060996, a Phase 3 study, was terminated before completion, sponsored by United Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to assess and compare the safety of continuous and daily subcutaneous Remodulin therapy in patients with critical limb ischemia (CLI) with no planned vascular interventional procedures; and to determine the effect of Remodulin on wound healing and treadmill walk distance.
Interventions
- DRUG Remodulin® (treprostinil sodium) Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-02 |
| Est. Completion | 2004-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060996
The ClinicalTrials.gov registry entry for NCT00060996 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Remodulin® (treprostinil sodium) Injection is the first listed.
NCT00060996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060996 about?
NCT00060996 is a clinical study titled "Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures". The purpose of this study is to assess and compare the safety of continuous and daily subcutaneous Remodulin therapy in patients with critical limb ischemia (CLI) with no planned vascular interventional procedures; and to determine the effect of Remodulin on wound healing and treadmill walk distance...
What is the current status of trial NCT00060996?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2003-02. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00060996?
The interventions under investigation include: Remodulin® (treprostinil sodium) Injection (DRUG).
Who is sponsoring clinical trial NCT00060996?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.